Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressing Autologous T Cells as an Immunotherapy for Children With Solid Tumors (CARE)

NCT04715191 is registered in ClinicalTrials.gov with Baylor College of Medicine as lead sponsor.

NCT NCT04715191
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04715191 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressing Autologous T Cells as an Immunotherapy for Children With Solid Tumors (CARE)
Lead sponsor
Baylor College of Medicine
Phase
Phase 1
Overall status
Recruiting
Start date
May 24, 2024
Completion date
July 3, 2042
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

liposarcoma, liver cancer, malignant rhabdoid tumor, rhabdomyosarcoma, wilms tumor, yolk sac tumor